P
Paul G. Richardson
Researcher at Harvard University
Publications - 1631
Citations - 174221
Paul G. Richardson is an academic researcher from Harvard University. The author has contributed to research in topics: Multiple myeloma & Bortezomib. The author has an hindex of 183, co-authored 1533 publications receiving 155912 citations. Previous affiliations of Paul G. Richardson include Broomfield Hospital & Dartmouth College.
Papers
More filters
Journal ArticleDOI
Blockade of PD-1 in Combination with Dendritic Cell/Myeloma Fusion Cell Vaccination Following Autologous Stem Cell Transplantation
Jacalyn Rosenblatt,Irit Avivi,Baldev Vasir,Lynne Uhl,Tami Katz,Poorvi Somaiya,Heidi Mills,Robin Joyce,James D. Levine,Dimitrios Tzachanis,Vassiliki A. Boussiotis,Katarina Luptakova,Jon E. Arnason,Natalie Drummy,Carol Delaney,Emma Breault,Vicki Held,Lina Bisharat,Nancy Giallombardo,Katharine Conway,Jamie Mortellite,Judith Wagoner,Michael Schickler,Rinat Rotem-Yehudar,Paul G. Richardson,Jacob P. Laubach,Nikhil C. Munshi,Kenneth C. Anderson,Jacob M. Rowe,Donald Kufe,David Avigan +30 more
TL;DR: These data demonstrate that CT-011 results in the expansion of tumor reactive lymphocytes in the early post-transplant period, providing an ideal platform for combination with a tumor vaccine.
Journal ArticleDOI
Bortezomib-Associated Peripheral Neuropathy: Relationship Between Clinical Neurophysiologic Evidence in Previously Untreated Multiple Myeloma Patients and Preclinical Characterization in a Mouse Model.
Paul G. Richardson,Jordi Bruna,Anthony A. Amato,Esther Udina,Constantine S. Mitsiades,Patrick Y. Wen,E. Tessa Hedley-Whyte,Anne Louise Oaklander,Johan Monbaliu,An Vynckier,Lee Silverman,Kenneth C. Anderson,Xavier Navarro +12 more
TL;DR: Overall, there appears to be good correspondence between clinical manifestations of bortezomib-associated PN and evidence from the mouse model, with both showing a predominantly sensory PN that affects both large and small fibers and is reversible.
Journal ArticleDOI
Phase 1 trial of 17-AAG in patients with relapsed and refractory multiple myeloma (MM)
Constantine S. Mitsiades,Asher A. Chanan-Khan,Melissa Alsina,Deborah Doss,B. Landrigan,D. Kettner,Maher Albitar,G. F. Cropp,Alison L. Hannah,Paul G. Richardson +9 more
TL;DR: In vivo, 17AAG extends the survival of mice after MM cells are injected and home to the marrow, and the MTD, toxicity and PK are defined.
Journal ArticleDOI
The Anti-Myeloma Effect of Bortezomib Is Associated with Osteoblastic Activity.
Maurizio Zangari,Kevin Najarian,Dixie Lee Esseltine,Choon-Kee Lee,Bart Barlogie,Francesca Elice,Michael J. Burns,Shmuel Yaccoby,Paul G. Richardson,Pieter Sonneveld +9 more
TL;DR: During bortezomib treatment, markers of osteoblastic activation (such as ALP) may predict response and response duration in patients with multiple myeloma, and this suggests that bone anabolism could affectMyeloma growth.
Journal ArticleDOI
Real-World and Clinical Trial Data in Relapsed/Refractory Multiple Myeloma (RRMM): Evaluating Treatment Duration and Comparing Effectiveness and Efficacy
Paul G. Richardson,Jesús F. San Miguel,Philippe Moreau,Roman Hájek,Meletios A. Dimopoulos,Antonio Palumbo,Katarina Luptakova,Tomas Skacel,Shaji Kumar,Kenneth C. Anderson +9 more
TL;DR: The efficacy benefits reported in phase 3 clinical trials in RRMM do not translate equally into the real-world setting, with evidence of substantially shorter outcomes in thereal-world vs clinical trial settings.